OBN Senior Executive Breakfast Club: Biosimilars
Event Start Date: Thursday, September 21, 2017 8:00 AM
Event End Date: Thursday, September 21, 2017 10:00 AM
We are pleased to invite you to apply to attend our next OBN Senior Executive Breakfast event, taking place at SCI in Belgravia on Thursday 21 September. The event will include insight and a round table discussion on the topic of:
‘Are Biosimilars and Biosuperiors the generic equivalent to small molecule therapeutics, and are they an opportunity or threat to the Biotech Industry?’
Our Industry Leading Speakers will share their opinions and insights on the Biosimilars and Biosuperiors market and will address whether Biosimilars will impact the future market for novel biologics and inhibit the opportunities for R&D Biotech companies. The current line-up includes:
Warwick Smith, who is the Director-General of the British Generic Manufacturers Association and the British Biosimilars Association (BBA). He is a member of the Board and Executive of the European Generic medicines Association (EGA), and was one of its Vice Presidents from 1995 to 2000.
Warwick will give a general overview of the industry.
Beatriz San Martín, is Partner and intellectual property specialist at Fieldfisher with a focus on the life sciences sector and emerging/disruptive technologies. Prior to pursuing a legal career, Beatriz was a scientist with a degree and a Wellcome Trust PhD and postdoc from the University of Cambridge specialising in genetics, cellular and molecular biology.
Beatriz will discuss regulatory aspects and challenges.
Siân Gill, is a Partner at Venner Shipley and a UK and European patent attorney specialising in patent applications in a broad spectrum of technical fields including pharmaceuticals, formulation technology and drug delivery.
Siân will discuss opportunities and threats of patent protection.
Kavya Gopal, has extensive experience in Biosimilars and was recently appointed the Head of Speciality UK for Sandoz. Sandoz are a Novartis Division and the world leaders in the production of biosimilars, generic antibiotics, dermatology and transplantation medicines.
Kavya will disccuss the development process and commercial opportunity of biosimilars.
More about the topic:
Biologics with estimated sales of $100 billion will come off patent by 2020, presenting major commercial opportunities for the development of Biosimilars and Biosuperiors. Our speakers will share their expert views on the potential growth and significant hurdles facing the wide-scale development and commercialisation of this emerging industry, including:
- When is a biological ripe for development as a biosimilar? Where’s the competition?
- Identifying and streamlining the technical and regulatory process in producing commercially viable BioSimilars
- The ‘Biosuperiors proposition’ – pros and cons
- Routes to commercial success – re-educating existing markets and/or aiming for new territories?
- Risk mitigation strategies
08:00 Registration and breakfast
08:30 Welcome by Dr John Harris, CEO of OBN (UK)
08:40 Keynote presentations
09:20 Q&A and delegate round-table discussions
10:00 Wrap up and close
SCI Headquarters, 14/15 Belgrave Square, London, SW1X 8PS
OBN Member: Free
OBN Non-Member: £25+VAT
Our Senior Executive Breakfast Clubs are a unique peer-to-peer networking platform for life sciences senior execs with all discussions held under Chatham House Rules which ensures full, frank and useful disclosure.
- Aimed at the Senior Executives of R&D companies and Investors
- Contact email@example.com for clarification if you are unsure if you qualify to attend or if you would like to suggest other people to invite
We look forward to welcoming you on the morning.